Pharmaceutical Lipid-Based Excipients Market Report 2026

The pharmaceutical lipid-based excipients market size has grown strongly in recent years. It will grow from $1.77 billion in 2025 to $1.86 billion in 2026 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to growth in poorly water-soluble drug pipelines, advancements in lipid formulation science, expansion of pharmaceutical manufacturing, rising use of oral delivery systems, regulatory support for lipid excipients.

The pharmaceutical lipid-based excipients market size is expected to see strong growth in the next few years. It will grow to $2.29 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to growth in complex drug formulations, increasing demand for enhanced drug absorption, expansion of biologics and oncology drugs, advancements in lipid technologies, rising focus on patient-centric formulations. Major trends in the forecast period include increasing use of lipid excipients for poorly soluble drugs, growing adoption in oral and parenteral formulations, rising demand for bioavailability-enhancing excipients, expansion of lipid-based drug delivery systems, increasing focus on natural and sustainable lipids.

The growing adoption of gene therapy is expected to drive the growth of the pharmaceutical lipid-based excipients market in the coming years. Gene therapy is a medical approach that involves altering or manipulating a person’s genes to treat or prevent disease. Its growth is supported by advancements in delivery systems, which allow for safe, efficient, and targeted transport of genetic material into cells. Pharmaceutical lipid-based excipients play a crucial role in gene therapy by enabling effective delivery systems, maintaining stability, and facilitating targeted transport of genetic material. They enhance therapeutic outcomes by protecting nucleic acids and promoting cellular uptake, thereby improving the effectiveness of modern treatments. For example, in December 2024, data from the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, reported that the FDA approved six gene therapy products in 2023, up from five approvals in 2022. As a result, the rise in gene therapy is contributing to the expansion of the pharmaceutical lipid-based excipients market.

Major companies operating in the pharmaceutical lipid-based excipients market are investing in initiatives such as advanced Centers of Excellence to drive innovation, strengthen formulation capabilities, support drug delivery research, and enhance their competitive position in emerging therapeutic areas. For instance, in November 2024, Gattefossé SAS, a France-based chemical manufacturing company, inaugurated a state-of-the-art Technical Center of Excellence in Mumbai to serve India’s growing pharmaceutical sector. The facility offers specialized laboratories and tailored support for excipient innovation, focusing on bioavailability, sustained-release, and topical formulations, while also reinforcing the company’s presence in the Asia-Pacific region. The advanced center includes pharmaceutical and personal care application labs designed to foster innovation, collaboration, and productivity.

In June 2024, CordenPharma, a Switzerland-based pharmaceutical company, partnered with Certest Biotec S.L. This collaboration aims to integrate Certest’s proprietary ionizable lipids into CordenPharma’s lipid nanoparticle (LNP) formulation services, enhancing RNA and DNA therapeutic development through combined expertise in lipid innovation, manufacturing, and regulatory compliance. Certest Biotec S.L. is a Spain-based biotechnology company specializing in drug delivery using lipid nanoparticles (LNPs) and active pharmaceutical ingredient (API) synthesis.

Major companies operating in the pharmaceutical lipid-based excipients market are Cargill Incorporated, BASF SE, Merck KGaA, FUJIFILM Corporation, Evonik Industries AG, DuPont de Nemours Inc., Stepan Company, Croda International, Ashland Corporation, NOF CORPORATION, CordenPharma, SEPPIC, Nippon Fine Chemical Co. Ltd., Cayman Chemical, ABITEC Corporation, Creative Biolabs, IOI Oleo GmbH, Lipoid, RuixiBiotechCo.Ltd, Biosynth.

Europe was the largest region in the pharmaceutical lipid-based excipients market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical lipid-based excipients market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical lipid-based excipients market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the pharmaceutical lipid-based excipients market by increasing costs of imported lipid raw materials and specialized processing equipment. These impacts are most evident in oral and parenteral formulation segments across Europe, North America, and Asia-Pacific. Higher tariffs have raised formulation costs. Positively, tariffs have encouraged domestic lipid processing and innovation in alternative excipient sourcing.

The pharmaceutical lipid-based excipients market research report is one of a series of new reports that provides pharmaceutical lipid-based excipients market statistics, including pharmaceutical lipid-based excipients industry global market size, regional shares, competitors with a pharmaceutical lipid-based excipients market share, detailed pharmaceutical lipid-based excipients market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical lipid-based excipients industry. This pharmaceutical lipid-based excipients market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical lipid-based excipients are inactive substances derived from lipids, used in drug formulations to aid in the delivery, stabilization, or absorption of the active pharmaceutical ingredient (API). They are designed to enhance drug solubility, stability, and bioavailability, particularly for drugs with poor water solubility.

The main types of pharmaceutical lipid-based excipients include oils, hydrogenated vegetable oils, glyceryl mono caprylate/caprate (GMCC), hard fats, medium-chain triglycerides, lecithin and phospholipids, sodium oleate, caprylic mono- and diglycerides, and others. Oils act as non-aqueous carriers that increase the solubility of lipophilic drugs and improve their oral bioavailability. These excipients are used in a variety of product formulations, including oral, parenteral, topical, ophthalmic applications, suppositories, and others. They support the treatment of numerous health conditions such as cardiovascular diseases, neurological disorders, cancer, metabolic disorders, hormonal imbalances, infectious diseases, and more. Lipid-based excipients are suitable for all age groups, including pediatric (0-18 years), adult (19-64 years), and geriatric (65+ years) populations. The primary end users are pharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and others.

The pharmaceutical lipid-based excipients market consists of sales of lipid excipients, specialty formulations, sterols, waxes, and glycolipids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.